Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2012; 3:369-380. doi:10.7150/jca.5111 This volume Cite

Research Paper

Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation

Michal Mego1,7*, Hui Gao1,6*, Bang-Ning Lee1,6, Evan N. Cohen1,6, Sanda Tin1,6, Antonio Giordano1,6, Qiong Wu1,6, Ping Liu3, Yago Nieto4, Richard E. Champlin4, Gabriel N. Hortobagyi2,6, Massimo Cristofanilli5, Naoto T. Ueno2,4,6✉, James M. Reuben1,6 ✉

1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;
2. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;
4. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX;
5. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA;
6. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX.
7. Current Address: National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic.
* MM and HG contributed equally to this study.

✉ Corresponding author: James M. Reuben, PhD. Professor, Department of Hematopathology, Unit 054, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. Or Naoto T. Ueno, MD, PhD. Professor, Department of Breast More

Citation:
Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 2012; 3:369-380. doi:10.7150/jca.5111. https://www.jcancer.org/v03p0369.htm
Other styles

File import instruction

Abstract

Background: Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer (MBC) patients treated by conventional dose chemotherapy. The aim of this study was to determine the role of CTCs and CTCs undergoing epithelial-mesenchymal transition (EMT) in metastatic breast cancer. We used the platform of high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (AHSCT) to study the CTCs and CTCs with EMT.

Patients and methods: CTCs were enumerated in 21 MBC patients before apheresis and 1 month after AHSCT. CD34-depleted apheresis products were analyzed for CD326+ epithelial and Aldefluor+ cancer stem cells (CSC) by flow cytometry and were depleted of CD45+ cells and assessed for EMT-inducing transcription factors (EMT-TF) by quantitative RT-PCR.

Results: Patients with ≥ 5 CTCs/7.5 mL of peripheral blood 1 month after AHSCT had shorter progression-free survival (PFS) (P=0.02) and overall survival (OS) (P=0.02). Patients with apheresis products containing high percentages of CD326+ epithelial cells or overexpressing EMT-TF had shorter PFS. In multivariate analysis, low percentage of CD326+ epithelial cells and response to HDCT with AHSCT were associated with longer PFS, whereas lower CTCs after AHSCT was associated with longer OS. High CTCs, 1 month after AHSCT correlated with shorter PFS and OS in MBC patients undergoing HDCT and AHSCT, while CTCs with EMT and CSCs phenotype in apheresis products are associated with relapse.

Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT.

Keywords: metastatic breast cancer, circulating tumor cells, epithelial-mesenchymal transition, high-dose chemotherapy, autologous hematopoietic stem cell transplantation.

Citation styles

APA
Mego, M., Gao, H., Lee, B.N., Cohen, E.N., Tin, S., Giordano, A., Wu, Q., Liu, P., Nieto, Y., Champlin, R.E., Hortobagyi, G.N., Cristofanilli, M., Ueno, N.T., Reuben, J.M. (2012). Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer, 3, 369-380. https://doi.org/10.7150/jca.5111.

ACS
Mego, M.; Gao, H.; Lee, B.N.; Cohen, E.N.; Tin, S.; Giordano, A.; Wu, Q.; Liu, P.; Nieto, Y.; Champlin, R.E.; Hortobagyi, G.N.; Cristofanilli, M.; Ueno, N.T.; Reuben, J.M. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J. Cancer 2012, 3, 369-380. DOI: 10.7150/jca.5111.

NLM
Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 2012; 3:369-380. doi:10.7150/jca.5111. https://www.jcancer.org/v03p0369.htm

CSE
Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. 2012. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 3:369-380.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use